Inocucor Corporation, a developer and producer of biological crop inputs for high-value produce and row crops, announced the final close of its Series B funding round at $15.9 million with participation by existing investors Cycle Capital Management (Montreal), Desjardins Innovatech (Montreal), TPG ART (San Francisco), and Pontifax AgTech (Los Angeles).
Inocucor uses its proprietary microbial consortia technology to combine multiple beneficial bacteria and yeasts into powerful soil and plant boosters that are economical for farmers and greenhouse growers, and safe for people and the environment.
The power of Inocucor science lies in their ability to use advanced microbiological techniques to isolate individual microbial strains based on their compatibility with one another and other factors.
Inocucor has identified and field-tested a group of 10 microbial strains that perform best for growers on farms and in greenhouses.
In producing microbial consortia products for field use, they maintain a consistent quality by subjecting each production batch to microbial, chemical/biochemical and bio-functional analysis. This ensures a high quality of performance when these products are used by their customers and commercial partners.